Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2023 Earnings Call Transcript
Matthew Scalo: Okay. Good afternoon, and welcome to the Myriad Genetics' First Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
Stay updated with breaking news from Genetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Matthew Scalo: Okay. Good afternoon, and welcome to the Myriad Genetics' First Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
Lucira Health (NASDAQ:LHDXQ – Get Rating) and Myriad Genetics (NASDAQ:MYGN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation. Valuation & Earnings This table compares Lucira Health and […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) issued an update on its FY23 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of ($0.36)-($0.24) for the period, compared to the consensus estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of ($0.36)-($0.24) for the period, compared to the consensus EPS estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad Genetics also updated its FY 2023 […]
Myriad Genetics (NASDAQ:MYGN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of ($0.36)-($0.24) for the period, compared to the consensus EPS estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad Genetics also updated its FY 2023 […]